Professional
Added to YB: 2025-01-09
Pitch date: 2025-01-07
NVO [bullish]
Novo Nordisk A/S
-55.17%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 81.80
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
turnaround
Protean Funds Scandinavia AB Portfolio Holdiing: Novo Nordisk A/S
NVO: Cagrisema phase III study miss caused 20% drop in Dec. Pharma stocks priced on 5+ year growth potential, so next-gen product not exceeding competitor is significant. Questions remain on study design & dosage. Still attractive for valuation, cash flows, innovation & shareholder returns. -0.5% net loss for year despite volatility.
Read full article (2 min)